Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission.
Brenner
M
M
St. Jude Children's Research Hospital, Memphis, Tennessee 38101.
Krance
R
R
Heslop
H E
HE
Santana
V
V
Ihle
J
J
Ribeiro
R
R
Roberts
W M
WM
Mahmoud
H
H
Boyett
J
J
Moen
R C
RC
D000208:Acute Disease; D000293:Adolescent; D001483:Base Sequence; D015415:Biomarkers / Q000032:analysis*; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation; D002066:Busulfan; D002469:Cell Separation; D002648:Child; D002675:Child, Preschool; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D003520:Cyclophosphamide; D004351:Drug Resistance; D005069:Evaluation Studies as Topic; D005819:Genetic Markers; D005822:Genetic Vectors; D006412:Hematopoietic Stem Cells; D006801:Humans; D007155:Immunologic Factors; D007223:Infant; D007258:Informed Consent; D007376:Interleukin-2; D019868:Kanamycin Kinase; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D015080:Mesna; D008969:Molecular Sequence Data; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000032:analysis / Q000235:genetics*; D011993:Recombinant Fusion Proteins; D012074:Remission Induction; D012107:Research Design; D012190:Retroviridae / Q000235:genetics; D012449:Safety; D014182:Transplantation, Autologous
D015415:Biomarkers; D005819:Genetic Markers; D007155:Immunologic Factors; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; D003520:Cyclophosphamide; D017853:Phosphotransferases (Alcohol Group Acceptor); D019868:Kanamycin Kinase; D002066:Busulfan; D015080:Mesna